Clinical Trials Directory

Trials / Unknown

UnknownNCT04202653

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

New Combination of ETV, TQ-A3334 and TQ-B2450 for the Treatment of Chronic Hepatitis B Virus Infection

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Tongji Hospital · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treatment.

Conditions

Interventions

TypeNameDescription
DRUGETVentecavir 0.5 mg qd
DRUGTQ-A3334TQ-A3334 po qw
DRUGTQ-B2450TQ-B2450 q3w iv

Timeline

Start date
2020-01-01
Primary completion
2020-12-31
Completion
2021-06-30
First posted
2019-12-17
Last updated
2019-12-19

Source: ClinicalTrials.gov record NCT04202653. Inclusion in this directory is not an endorsement.